August 10, 2026

To,
Listing/ Compliance Department
BSE LTD.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

SCRIP CODE: 543748

To,
Listing/ Compliance Department
National Stock Exchange of India Limited
"Exchange Plaza", Plot No. C/1,
G Block, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

SYMBOL: AARTIPHARM

Dear Sir/Madam,

Sub: Results Presentation
Ref: Regulation 30 of the SEBI (LODR) Regulations 2015

Please find enclosed herewith the Q1 FY27 Results Presentation of the Company for your records.

The same is also being uploaded on Company's website https://www.aartipharmalabs.com/presentation

Please take the same on your records.

Thanking you,

Yours faithfully,
For AARTI PHARMALABS LIMITED

Jeevan Bhargav Mondkar
Digitally signed by Jeevan Bhargav Mondkar
Date: 2026.08.10 13:10:20 +05'30'

JEEVAN MONDKAR
COMPANY SECRETARY AND LEGAL HEAD
ICSI M. NO. A22565

Encl. a/a.

AARTI
PHARMALABS

INVESTOR PRESENTATION

August 2026

SNAPSHOT

AARTI PHARMALABS

25+ Years of Pharmaceutical Excellence

220+ Products

63 Patents Filed

500+ Global Clients

50+ Export Countries

3 State-of-the-art R&D facilities

7 Manufacturing Units

3 USFDA Units

2,400+ Employees

60 US DMF

44 CEP

15-20% Global Market Share in Xanthine

0.32x Net Debt/Equity

AA- Credit rating

GOLD | Top 5% ecovadis Sustainability Rating APR 2025

CDP DRIVING SUSTAINABLE ECONOMIES

SCIENCE BASED TARGETS DRIVING AMBITIOUS CORPORATE CLIMATE ACTION

1 COMPANY OVERVIEW

2 BUSINESS OVERVIEW

3 STRATEGIC OVERVIEW

4 FINANCIAL OVERVIEW

COMPANY OVERVIEW

- Aarti Pharmalabs Limited (APL) is part of the Aarti group – a diversified chemical conglomerate with group turnover of INR 145+ bn (FY26)
- Globally recognized manufacturer of generic API, Xanthine derivatives (Worlds third largest capacity) and a leading player in CDMO/CMO services
- Demonstrated strong expertise in development of robust & cost-effective process for rapid scale up and commercial production
- Received accreditation from several agencies, including USFDA, EU GMP, EDQM (European Pharmacopoeia), KFDA (Korea), and COFEPRIS (Mexico)
- Strategically located in western India with proximity to ports

HIGHLIGHTS

One of the leading small molecule CDMO/CMO company in India.

Regulatory focussed operations with expertise in novel chemistries;

Largest manufacturer of Xanthine Derivatives in India

STANDALONE REVENUE (INR Mn) & EBITDA MARGINS (%)



GEOGRAPHICAL SALES (Q1-FY27)



KEY MILESTONES

AARTI PHARMALABS

1

1984

Aarti Organic Private Limited was incorporated

2

2001

Commissioned the first API manufacturing unit in Dombivli (Unit 1) and started the Xanthine unit

3

2005

Commissioned the first API manufacturing unit in Tarapur for Regulated Markets (Unit 4)

4

2008

Successfully completed the USFDA & EUGMP audit for Tarapur Unit 4

5

2009

Successfully completed the USFDA audit at the Intermediate facility (CSD) in Vapi

6

2013

Received EUGMP approval for Bicalutamide for the Oncology block at Unit 4

7

2016

Commissioned Caffeine production at Unit 5 with a capacity of 100 Metric Tons (MT) per month

8

2019

Successfully completed an audit by EDQM for Bicalutamide for the Oncology block at Unit 4

9

2022

- Expanded block for CSD in Vapi and API in Tarapur units
- Acquired land at Atali for future growth
- Successfully demerged the pharmaceutical business of Aarti Industries Limited to Aarti Pharmalabs Limited

10

2023

- Operationalized the third R&D center
- Secured USFDA approval for Dombivli Unit
- Commercialized Block V at Tarapur Unit 4
- Enhanced Xanthine capacity to 5,000 TPA

11

2024

- Started 21 MW solar power project at Akola, Maharashtra
- Expansion of semi-commercial production block at Vapi

12

2025

Commissioned Phase 1 at Atali greenfield site with 450+ kL reactor capacity

13

2026

- Inaugurated Tarapur(Unit 5), adding 3,600 TPA to reach a total capacity of 9,600 TPA

GEOGRAPHICAL PRESENCE



LOCATION	MANUFACTURING UNITS	CERTIFICATIONS & AUDIT DATE
Dombivali	Unit - I (API, Intermediates, CDMO)	USFDA - Jun 2022
Vapi	Unit - II (API, Intermediates, CDMO) Custom Synthesis Division	USFDA - Sep 2009, Aug 2017
Tarapur	Unit – III (Xanthine Unit)	
	Unit – IV (API, CDMO-API)	USFDA – Mar 2008, Sep 2011, Mar 2015, Dec 2016, Feb 2020 EUGMP – Apr 2008, May 2012, Aug 2013, Jan 2015 EDQM – Sep 2019, KFDA – Nov 2017, COFEPRIS – Apr 2017, May 2017
	Unit - V (Xanthine Unit)	
	Unit - VI (Intermediate unit of Xanthine, speciality & allied products)	
Atali	Atali Unit (Intermediates, CDMO)	

HEAD OFFICE

R&D CENTER

MANUFACTURING UNIT

MANUFACTURING CAPABILITIES

END TO END CAPABILITIES UNDER ONE UMBRELLA

CAPABILITIES

Hydrogenation facilities from lab-scale to manufacturing scale (0.1-10 KL reactors)

Cryogenic reactors operating within a temperature range of -100°C to +150°C

Continuous manufacturing, flow chemistry & bio-catalysis reaction

HPAPI (Cytotoxic/Oncology) and Cortico Steroids development and manufacturing

25+ years of experience in pharmaceuticals manufacturing for global clients

Impeccable regulatory track record and facilities approved by several pharmaceutical clients from EHS and Quality perspectives

Dedicated Cyanation Manufacturing Block

Strong expertise in development of robust and cost-effective processes for rapid scale-up and commercial production

TECHNICAL CAPABILITIES | **MANUFACTURING CAPABILITIES**

RESEARCH & DEVELOPMENT

AARTI PHARMALABS

3
State of the art R&D Centers at Maharashtra & Gujarat

40+
Products developed and manufactured on kilo-lab scale in FY25

25+
New products launched at plant scale in FY25

7.4%
R&D Spend (as a percent of API+Int & CDMO sales) in FY26

21
PhDs

122
R&D Process Scientists

65 Cr
R&D Spend in FY26

61
APIs commercialized

63
Process Patents Filed

31
Patents Granted

1

COMPANY OVERVIEW

2

BUSINESS OVERVIEW

3

STRATEGIC OVERVIEW

4

FINANCIAL OVERVIEW

XANTHINE DERIVATIVES & ALLIED PRODUCTS

- World's third-largest and India's largest manufacturer of Xanthine Derivatives, including Caffeine (largest capacity in India), Theophylline Anhydrous, Aminophylline, Etophylline, and Theophylline.
- Non-Chinese dependent and fully backward integrated manufacturer of Xanthine derivatives, offering strong geographical diversification amidst “China+1” shift.
- Two dedicated plants at Tarapur, Maharashtra with a combined capacity of 9,600+ MTPA for producing Xanthine Derivatives.
- Capacity expanded from 5000 MTPA to 9,600+ MTPA, with phased ramp-up underway till FY27 end.
- Expanded capacity is expected to drive global market share from 15–20% to 20–25%.

END USE

Cola Drinks | Energy Drinks | Pharmaceutical | Nutraceutical

CERTIFICATIONS

SALES QUANTITY SPLIT (Q1-27)



GEOGRAPHICAL SALES SPLIT (Q1-FY27)



API & INTERMEDIATES

- Specialized player in the development and manufacturing of HPAPIs, catering to the demand for critical drugs used in oncology, corticosteroids, and cytotoxic medicines.
- Backward integrated for most APIs, with control over entire production value chain and ensuring high-quality intermediates.
- With USFDA approved manufacturing facilities and dedicated US, EU and Japan approvals, APL enjoys a distinct advantage over competition
- Preferred partner in regulated markets driven by robust regulatory documentation and IPR support
- 1,500+ KL multipurpose reactor capacity (fungible) and 14 API finished lines

KEY HIGHLIGHTS

61	APIs Commercialized
11	New APIs under development (R&D / validation)
60	US DMF Approvals
44	CEP Approvals
140+	Intermediates

THERAPEUTIC SEGMENT

CARDIOVASCULAR
ANTI ASTHAMATIC
ANTI CANCER
ONCOLOGY
ANTI DIABETIC
CNS AGENT
SKIN CARE
OVERACTIVE BLADDER
CALCIMIMETIC
DECONGESTANT
ANTI THALASSAEMIC
ANALGESIC

MARKET SEGMENTATION (Q1-FY27)



GEOGRAPHICAL SALES SPLIT (Q1-FY27)



CDMO & CMO

- Amongst leading small molecule CDMO/CMO players in India, working with big pharma, innovators and biotech companies.
- Offering end to end services including process development and manufacturing of KSMs, RSMs, Intermediates & GMP APIs for small molecule NCEs, from early clinical phase (Phase 1,2,3), launch to commercial supplies
- Experienced in complex chemistries like cyanation, flow chemistry, nucleotides amongst others.
- Supported by 3 R&D centers and pilot facilities focusing on CDMO. Presently working with 22 customers on 57 active projects, of which 37 are in the commercial stage and 20 are under different stages of development, both at customer's end.
- Expanding on-ground sales presence to USA and EU, to strategically enhance CDMO global footprint.

SERVICES OFFERED

End-to-end solutions from synthetic route design to commercial manufacturing, specializing in HPAPIs, cryogenic reaction & corticosteroids development

Comprehensive services like
1) Robust process development (DoE & QbD studies)
2)Process validation and
3)Analytical method development & validation

Strong CMC documentation expertise to ensure smooth regulatory approvals.





Note: In chart, FY27E indicates estimated sales for FY27

SEGMENTAL SHARE & QUARTERLY HIGHLIGHTS

REVENUE BREAKUP Q1FY27



OPERATIONAL HIGHLIGHTS Q1FY27

- Q1FY27 production at the Unit 4 Steroid API Block was temporarily impacted by a 6-week debottlenecking shutdown, successfully unlocking a one-third capacity increase.
- Geopolitical tension have kept RM prices at elevated levels. However, we are beginning to see early indications of supply chain easing.

1

COMPANY OVERVIEW

2

BUSINESS OVERVIEW

3

STRATEGIC OVERVIEW

4

FINANCIAL OVERVIEW

CAPEX UPDATE

Brownfield Capex – Atali Block 2

Site	Unit 7, Atali, Gujarat
Estimated Investment	INR 149 crores
Estimated Capacity	~405 KL
Timeline	Commercialization by H2FY28
Product Focus	CDMO/CMO

Strategic Rationale

- Dedicated for certain CDMO / CMO projects, thereby ensuring supply continuity to large pharma customers
- Cost effective design to yield better payback

FUTURE OUTLOOK

Targeting

15-18%

Revenue & EBITDA CAGR

Over the Next 3-4 Years

- FY26 CAPEX reached ~ INR 400 cr; FY27 outlook expected at similar levels
- Initiating R&D investment in FY27 towards TIDES (Peptides & Oligonucleotides) to expand portfolio capabilities.
- Announced capex for Atali Block 2 for specific CDMO / CMO projects; Groundbreaking planned in Q3FY27

1
COMPANY OVERVIEW

2
BUSINESS OVERVIEW

3
STRATEGIC OVERVIEW

4
FINANCIAL OVERVIEW

QUARTERLY STANDALONE INCOME STATEMENT

PARTICULARS (INR Mn)	Q1-FY27	Q4-FY26	Q-o-Q	Q1-FY26	Y-O-Y
Operational Revenue	**5,346**	**5,797**	**(7.8)%**	**3,753**	**42.4%**
Operating Expenses	4,019	4,456	(9.8)%	2,802	43.4%
EBITDA	**1,327**	**1,341**	**(1.0)%**	**951**	**39.5%**
EBITDA Margin (%)	***24.82%***	***23.13%***	***169 Bps***	***25.34%***	***(52) Bps***
Depreciation and Amortisation	300	282	6.4%	228	31.6%
Finance costs	129	169	(23.7)%	68	89.7%
Foreign Exchange (Gain)/Loss	(35)	170	NA	38	NA
Other Income	29	106	(72.6)%	8	NA
PBT before Exceptional Items	**962**	**826**	**16.5%**	**625**	**53.9%**
Exceptional Items	-	-	NA	-	NA
PBT	**962**	**826**	**16.5%**	**625**	**53.9%**
Tax Expense	249	206	20.9%	147	69.4%
PAT	**713**	**620**	**15.0%**	**478**	**49.2%**
PAT Margin (%)	***13.34%***	***10.70%***	***264 Bps***	***12.74%***	***60 Bps***
Other Comprehensive Income	18	(35)	NA	10	80.0%
Total Comprehensive Income	**731**	**585**	**25.0%**	**488**	**49.8%**
Diluted EPS (INR)	7.86	6.84	14.9%	5.27	49.1%

 # Recognition of fair value movement on a long-dated USD forward contract under FVTPL impacted reported profitability during the period, with previous quarterly figures restated accordingly.

QUARTERLY CONSOLIDATED INCOME STATEMENT

PARTICULARS (INR Mn)	Q1-FY27	Q4-FY26*	Q-o-Q	Q1-FY26	Y-O-Y
Operational Revenue	**5,358**	**5,826**	**(8.0)%**	**3,862**	**38.7%**
Operating Expenses	4,032	4,525	(10.9)%	2,910	38.6%
EBITDA	**1,326**	**1,301**	**1.9%**	**952**	**39.3%**
EBITDA Margin (%)	***24.75%***	***22.33%***	***242 Bps***	***24.65%***	***10 Bps***
Depreciation and Amortisation	300	282	6.4%	228	31.6%
Finance costs	129	169	(23.7)%	68	89.7%
Foreign Exchange (Gain)/Loss	(35)	170	NA	38	NA
Other Income	5	81	(93.8)%	8	(37.5)%
PBT before Joint Venture & Exceptional Items	**937**	**762**	**23.0%**	**626**	**49.7%**
Exceptional Items (Net of Tax Expenses)	-	-	NA	-	NA
PBT before Joint Venture	**937**	**762**	**23.0%**	**626**	**49.7%**
Share of JV	74	55	34.5%	(18)	NA
PBT	**1,011**	**817**	**23.7%**	**608**	**66.3%**
Tax Expense	250	206	21.4%	148	68.9%
PAT	**761**	**611**	**24.5%**	**460**	**65.4%**
PAT Margin (%)	***14.20%***	***10.49%***	***371 Bps***	***11.91%***	***229 Bps***
Other Comprehensive Income	17	(48)	NA	10	70.0%
Total Comprehensive Income	**778**	**563**	**38.2%**	**470**	**65.5%**
Diluted EPS (INR)	8.39	6.74	24.5%	5.08	65.2%

 # Recognition of fair value movement on a long-dated USD forward contract under FVTPL impacted reported profitability during the period, with previous quarterly figures restated accordingly.

**Note: As intimated to the stock exchange on 1st April 2025, regarding the addendum to the SHA with Ganesh Polychem Limited, the entity becomes a joint venture of the company with effect from April 1, 2025, and pursuant to the same the consolidated accounts are prepared using the equity method of accounting as required by the relevant Ind AS. Accordingly, current period numbers are not comparable with previous periods.*

HISTORICAL STANDALONE INCOME STATEMENT

PARTICULARS (INR Mn)	Q1-FY27	FY26	FY25	FY24
Operational Revenue	**5,346**	**17,976**	**17,714**	**15,021**
Operating Expenses	4,019	13,915	13,449	11,560
EBITDA	**1,327**	**4,061**	**4,265**	**3,461**
EBITDA Margin (%)	***24.82%***	***22.59%***	***24.08%***	***23.04%***
Depreciation and Amortisation	300	1,043	791	660
Finance costs	129	469	256	166
Foreign Exchange (Gain)/Loss	(35)	332	(17)	-
Other Income	29	153	128	110
PBT before Exceptional Items	**962**	**2,370**	**3,363**	**2,745**
Exceptional Items	-	28	-	-
PBT	**962**	**2,342**	**3,363**	**2,745**
Tax Expense	249	580	790	738
PAT	**713**	**1,762**	**2,573**	**2,007**
PAT Margin (%)	***13.34%***	***9.80%***	***14.53%***	***13.36%***
Other Comprehensive Income	18	(39)	(51)	1
Total Comprehensive Income	**731**	**1,723**	**2,522**	**2,008**
Diluted EPS (INR)	7.86	19.42	28.38	22.14

 # Recognition of fair value movement on a long-dated USD forward contract under FVTPL impacted reported profitability during the period, with previous year figures restated accordingly.

HISTORICAL CONSOLIDATED INCOME STATEMENT

PARTICULARS (INR Mn)	Q1-FY27	FY26*	FY25	FY24
Operational Revenue	**5,358**	**18,194**	**21,151**	**18,526**
Operating Expenses	4,032	14,170	16,507	14,666
EBITDA	**1,326**	**4,024**	**4,644**	**3,860**
EBITDA Margin (%)	***24.75%***	***22.12%***	***21.96%***	***20.84%***
Depreciation and Amortisation	300	1,043	869	732
Finance costs	129	469	269	172
Foreign Exchange (Gain)/Loss	(35)	332	(17)	-
Other Income	5	97	84	49
PBT before Joint Venture & Exceptional Items	**937**	**2,277**	**3,607**	**3,005**
Exceptional Items (Net of Tax Expenses)	-	28	-	-
PBT before Joint Venture	**937**	**2,249**	**3,607**	**3,005**
Share of JV	74	80	-	-
PBT	**1,011**	**2,329**	**3,607**	**3,005**
Tax Expense	250	582	883	836
PAT	**761**	**1,747**	**2,724**	**2,169**
PAT Margin (%)	***14.20%***	***9.60%***	***12.88%***	***11.71%***
Other Comprehensive Income	17	(62)	(98)	(4)
Total Comprehensive Income	**778**	**1,685**	**2,626**	**2,165**
Diluted EPS (INR)	8.39	19.25	30.04	23.93

 # Recognition of fair value movement on a long-dated USD forward contract under FVTPL impacted reported profitability during the period, with previous year figures restated accordingly.

**Note: As intimated to the stock exchange on 1st April 2025, regarding the addendum to the SHA with Ganesh Polychem Limited, the entity becomes a joint venture of the company with effect from April 1, 2025, and pursuant to the same the consolidated accounts are prepared using the equity method of accounting as required by the relevant Ind AS. Accordingly, current period numbers are not comparable with previous periods.*

HISTORICAL STANDALONE BALANCE SHEET

AARTI PHARMALABS

ASSETS (INR Mn)	FY24	FY25	FY26
Assets			
Non-current assets			
Property, plant and equipment	9,160	10,135	13,359
Capital work-in-progress	785	3,009	3,052
Right-to-use assets	205	153	655
Other Intangible assets	169	306	360
Intangible assets under development	584	678	879
Financial assets			
Investment in Subsidiary & Joint Control	135	135	135
Investments (others)	303	276	305
Loan	59	73	78
Other Financial Assets	107	135	352
Other non-current assets	122	208	168
Total of Non-current assets	**11,629**	**15,108**	**19,343**
Current assets			
Inventories	5,822	5,442	6,362
Financial assets			
Investments	-	159	-
Trade receivables	4,488	5,526	5,866
Cash and cash equivalents	218	28	55
Bank balances other than above	4	7	11
Loans	9	8	5
Other financial assets	63	11	-
Other current assets	706	875	1,536
Current Tax Assets (Net)	31	32	99
Total of Current assets	**11,340**	**12,088**	**13,934**
Total Assets	**22,969**	**27,196**	**33,277**

EQUITY & LIABILITIES (INR Mn)	FY24	FY25	FY26
Equity & Liabilities			
Equity share capital	453	453	453
Other equity	15,762	17,986	19,370
Total equity attributable to equity holders	**16,215**	**18,439**	**19,823**
Liabilities			
Non-current liabilities			
Financial liabilities			
Borrowings	-	1,036	1,858
Lease liabilities	167	117	522
Other Financial Liabilities	-	150	394
Provisions	53	71	78
Deferred Tax Liabilities (Net)	979	1,196	1,343
Total of Non-current liabilities	**1,199**	**2,570**	**4,195**
Current liabilities			
Financial liabilities			
Borrowings	2,508	2,913	4,998
Lease liabilities	45	50	166
Trade Payables	2,548	2,490	3,243
Other financial liabilities	284	466	637
Provisions	62	105	112
Current Tax Liabilities (Net)	-	-	-
Other Current Liabilities	108	163	103
Total of Current liabilities	**5,555**	**6,187**	**9,259**
Total Liabilities	**6,755**	**8,757**	**13,454**
Total Equity & Liabilities	**22,969**	**27,196**	**33,277**

HISTORICAL CONSOLIDATED BALANCE SHEET

ASSETS (INR Mn)	FY24	FY25	FY26
Non-current assets			
Property, plant and equipment	9,942	10,887	13,359
Capital work-in-progress	785	3,066	3,052
Right-to-use assets	205	154	655
Goodwill	18	18	-
Other Intangible assets	169	307	360
Intangible assets under development	584	678	879
Financial assets			
Investments (others)	368	292	1,938
Loans	59	73	78
Other Financial Assets	113	140	354
Other non-current assets	122	227	169
Total of Non-current assets	**12,365**	**15,842**	**20,844**
Current assets			
Inventories	6,429	5,876	6,403
Financial assets			
Investments	704	476	-
Trade receivables	5,193	5,754	5,833
Cash and cash equivalents	236	67	85
Bank balances other than above	4	19	11
Loans	13	10	5
Other financial assets	63	12	-
Other current assets	780	968	1537
Current Tax Assets (Net)	34	-	99
Total Current assets	**13,456**	**13,182**	**13,973**
Total Assets	**25,821**	**29,024**	**34,817**

EQUITY & LIABILITIES (INR Mn)	FY24	FY25	FY26
Equity share capital	453	453	453
Other equity	17,117	19,446	20,793
Total Equity	**17,570**	**19,899**	**21,246**
Liabilities			
Non-current liabilities			
Financial liabilities			
Borrowings	-	1,036	1,858
Lease liabilities	167	117	522
Non Current financial liabilities	-	77	394
Provisions	61	81	78
Deferred Tax Liabilities (Net)	1,079	1,284	1,343
Total of Non-current liabilities	**1,307**	**2,595**	**4,195**
Current liabilities			
Financial liabilities			
Borrowings	2,641	2,928	4,998
Lease liabilities	45	51	166
Trade Payables	3,783	2,778	3,346
Other financial liabilities	302	474	651
Provisions	63	117	112
Current Tax Liabilities (Net)	-	11	-
Other Current Liabilities	110	171	103
Total of Current liabilities	**6,944**	**6,530**	**9,376**
Total Liabilities	**8,251**	**9,125**	**13,571**
Total Equity & Liabilities	**25,821**	**29,024**	**34,817**

CONSOLIDATED FINANCIAL HIGHLIGHTS

OPERATIONAL INCOME (INR Mn)



EBITDA (INR Mn) & EBITDA MARGINS (%)



PAT (INR Mn) & PAT MARGINS (%)



Net Debt to Equity (X)



ROCE (%) & ROE (%)



 # Recognition of fair value movement on a long-dated USD forward contract under FVTPL impacted reported profitability during the period, with previous year figures restated accordingly.

**Note: As intimated to the stock exchange on 1st April 2025, regarding the addendum to the SHA with Ganesh Polychem Limited, the entity becomes a joint venture of the company with effect from April 1, 2025, and pursuant to the same the consolidated accounts are prepared using the equity method of accounting as required by the relevant Ind AS. Accordingly, current period numbers are not comparable with previous periods.*

CAPITAL MARKET INFORMATION

SHARE PRICE UP TO 30th June, 2026



PRICE DATA (AS ON 30th June, 2026)	INR
Face Value	5.00
Market Price	681.15
52 Week H/L	971.50/583.85
Market Cap (Mn)	61,751.53
Equity Shares Outstanding (Mn)	90.66
1 Year Avg Trading Volume ('000)	267.71

SHAREHOLDING PATTERN (AS ON 30th June, 2026)



DISCLAIMER

Aarti Pharmalabs Limited

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management of Aarti Pharmalabs Ltd. (Company), which are expressed in good faith and in their opinion reasonable, including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment.

Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments.

This presentation is confidential and may not be copied or disseminated, in whole or in part, and in any manner.

Valorem Advisors Disclaimer:

Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.

For further details, please feel free to contact our Investor Relations Representatives:

Mr. Anuj Sonpal
Valorem Advisors
Tel: +91-22-3507 5100
Email : aarti@valoremadvisors.com
To access the Investor Kit link and/or request a meeting click here: https://www.valoremadvisors.com/aarti

THANK YOU

AARTI PHARMALABS LIMITED